Delayed phase III study caused Novo Nordisk to exit hormone test contract

A late-stage study of hormone growth deficiency test Macrilen in children was postponed earlier this year, and the Danish pharmaceutical firm subsequently decided to end its agreement with developer Aeterna Zentaris.

Photo: Tidsvilde Stine/Ritzau Scanpix

Around four years after Novo Nordisk spent a sum nearing DKK 1.2bn (USD 161m) for diagnostic test Macrilen, the pharmaceutical company has decided to return the licensing rights to the original owner, biotech firm Aeterna Zentaris.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs